AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05306015 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Give routine treatment and care, and increase or decrease the dose or adjust according to the patient's condition in accordance with the doctor's advice. Before surgery, we will introduce the level of medical care involved in the surgery and the equipment of our hospital. Inform the patient of the surgical process and possible pain, and explain in detail the cause, location and characteristics of the pain, including the time when the pain will appear and last. Instruct patients to stabilize their emotions and maintain a calm state of mind. As far as possible to meet the patient's intraoperative care needs, give psychological care, wear a headband to collect EEG signals, but do not intervene in mindfulness meditation.
Study NCT06077786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06474
Description: Oral solution
Study NCT06077786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Lu AG06474
Description: Oral solution
Study NCT05176704 — intervention group
Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
Study NCT06549725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: software Lipidica
Description: The investigational medical device software (MDSW) Lipidica processes and analyses data inputs from the analysis of lipid profile in human plasma using an in-house in vitro diagnostic medical device.
Study NCT06549725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: software Lipidica
Description: The investigational medical device software (MDSW) Lipidica processes and analyses data inputs from the analysis of lipid profile in human plasma using an in-house in vitro diagnostic medical device.
Study NCT06549725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasonography
Description: Endoscopic ultrasonography - maximum frequency: 3 times during the participation
Study NCT06549725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance
Description: Magnetic resonance - maximum frequency: 3 times during the participation
Study NCT06549725 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: laboratory examination
Description: Lipidomic analysis, CA 19-9, CEA, HbA1c and hCG levels assessment (hCG only in women of childbearing potential in Arm 2)
Study NCT06549725 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: laboratory examination
Description: Lipidomic analysis, CA 19-9, CEA, HbA1c and hCG levels assessment (hCG only in women of childbearing potential in Arm 2)
Study NCT06077786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Capsule
Study NCT06077786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Capsule
Study NCT06077786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule
Study NCT06549725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: computed tomography - maximum frequency: 3 times during the participation
Study NCT05215561 — intervention group
Intervention type: OTHER
Intervention: Cosentyx
Description: There is no treatment allocation. Patients administered Cosentyx by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT06362642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: First-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.
Study NCT06362642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Antifungal treatment that is a potent inhibitor of CYP3A4.
Study NCT06160206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT06160206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06160206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05696418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with a Mobile Bearing system.
Description: The prostheses will be cruciate scarifying cemented DePuy Synthes PFC Sigma with a Mobile Bearing system without resurfacing the patella.
Study NCT05696418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with a Fixed Bearing system.
Description: The prostheses will be cruciate scarifying cemented DePuy Synthes PFC Sigma with a Fixed Bearing system without resurfacing the patella.
Study NCT06160206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06160206 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo radiation therapy
Study NCT06160206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06160206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Given IV
Study NCT06338670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Osia 3 Sound Processor
Description: Osia 3 Sound Processor including sound processor magnets and Osia 3 Aqua +
Study NCT06338670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear™ Osia® 2 Sound Processor
Description: Osia® 2 Sound Processor
Study NCT05646979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT group
Description: EFT protocol will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
Study NCT06513416 — intervention group
Intervention type: PROCEDURE
Intervention: Elective upper abdominal surgery
Description: The included elderly patients are those who are preparing for elective upper abdominal surgery and the surgery time exceeds 2 hours.
Study NCT06290024 — intervention group
Intervention type: DEVICE
Intervention: A multi-center clinical longitudinal study of neuropathic pain by collecting data on patients' brain physiology and cognitive function
Description: Using the use of pain visual analog scale (VAS), digital pain grading method (NRS), neuropathic pain assessment scale (DN4), sleep quality (Pittsburgh sleep quality index, Ascens insomnia scale), social support assessment scale (SSQ), Montreal cognitive assessment scale (MoCA), Barrett impulse scale (BIS), anxiety and depression score (GAD-7, PHQ-9), emotional tasks, cognitive function (N-back, time perception, delay-discount), electroencephalogram (EEG), near-infrared brain function imaging (fNIRS) and other indicators to study the dynamic changes of various factors in the process of acute pain.
Study NCT05358249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: KRAS G12C inhibitor, oral
Study NCT04830540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OOFOS Recovery Footwear
Description: The OOFOS shoes/ sandals are a commercially available footwear with a compliant, energy absorbing midsole material.
Study NCT05358249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: MEK inhibitor, oral
Study NCT05358249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK4/6 inhibitor, oral
Study NCT05358249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: EGFR inhibitor, intravenous
Study NCT05783960 — intervention group
Intervention type: OTHER
Intervention: administration questionary
Description: Questionnaire will be compared to 24h sodium and potassium urinary excretion (reference). A Bayesian network and a multiple regression will be used to validate the questionary
Study NCT06350513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animation movie, story book
Description: Animation movie: For this study, an animated film (Professor bumblebee animation) prepared for newly diagnosed children with type 1 diabetes will be shown in the experimental group. This is an approximately 10 minute film produced by Life for a children's center in New South Wales (DIABETES AUSTRALIA). The animated film will be translated into Turkish and sent to experts (specialists in the field of Children and Diabetes) for expert opinion. It will be shown to children after all permissions have been obtained following expert opinions. This animated movie is a guide to diabetes for children. Additionally, the storybook will be given as a gift for the children in the experimental group to read.~Story Book: It is an educational booklet version of the Professor Bumblebee animation translated into Turkish and illustrated. The aim here is to serve as an auxiliary tool for newly diagnosed T1D children to look at later and where they are confused.
Study NCT06350513 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Animation movie, story book
Description: Animation movie: For this study, an animated film (Professor bumblebee animation) prepared for newly diagnosed children with type 1 diabetes will be shown in the experimental group. This is an approximately 10 minute film produced by Life for a children's center in New South Wales (DIABETES AUSTRALIA). The animated film will be translated into Turkish and sent to experts (specialists in the field of Children and Diabetes) for expert opinion. It will be shown to children after all permissions have been obtained following expert opinions. This animated movie is a guide to diabetes for children. Additionally, the storybook will be given as a gift for the children in the experimental group to read.~Story Book: It is an educational booklet version of the Professor Bumblebee animation translated into Turkish and illustrated. The aim here is to serve as an auxiliary tool for newly diagnosed T1D children to look at later and where they are confused.
Study NCT05753748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Eradication Therapy
Description: Endoscopic eradication therapy is a procedure performed to destroy the precancerous cells at the bottom of your esophagus, so that healthy cells can grow in their place. It involves procedures to either remove precancerous tissue or burn it. These procedures are performed through the endoscope.
Study NCT05381428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin suppository
Description: Control Group: Patients will be randomized to receive a 100 mg indomethacin suppository will be administered immediately before the endoscopic procedure (20-30 minutes) and saline infusion will be given as needed.
Study NCT05381428 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository and high-flow lactated ringer infusion combination
Description: Interventional group: Patients will be randomized to receive an indomethacin suppository that will be administered immediately before (20-30 minutes) the endoscopic procedure in combination with a lactated Ringer's infusion that will be administered with the following weight-based schedule: 3 cc/kg/h during ERCP, a bolus of 20 cc/kg after ERCP, and again 3 cc/kg/h for 8 hours after ERCP.
Study NCT06150677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voluntary apnoea
Description: Static apneas at high lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds (9 cycles of 30s apnea - 10s normal breathing, until completing the 6 minutes).
Study NCT05376267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming,~A zero hour cooling duration (normothermia) treatment arm will be opened for enrollment if there is not an increase in the treatment effect across the durations. Alternatively, longer durations (84 or 96 hours) will be opened for enrollment if the treatment effects are increasing (rather than plateauing or decreasing) through 72 hours.
Study NCT06559800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YourSkills: Cognitive behavioral therapy for children/youth with role-plays in virtual reality
Description: A program for children/youth with anger problems or aggressive behaviors based on social learning theory and cognitive behavior therapy (CBT), incorporating virtual reality (VR) when conducting brief role-plays. The program includes similar strategies as other CBT-oriented programs for anger problems, with the addition of VR for practicing skills.
Study NCT06408519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (open-label)
Description: P-Tabletten weiss 10mm (Lichtenstein, Zentiva) pills 3x/day
Study NCT06408519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Ibuprofen pills 3x/day
Study NCT06422286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser
Description: children will be allocated to the device then the gag reflex will be re-evaluated
Study NCT06422286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microcurrent stimulation
Description: children will be allocated to the device then the gag reflex will be re-evaluated
Study NCT06422286 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: children will be allocated to a deactivated meridian pen
Study NCT05925972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plane block
Description: Plane block application in laparoscopic hysterectomies
Study NCT05541198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Injury Prevention Care Bundle
Description: 1. Risk Assessment~2. Skin Assessment~3. Skin Care~4. Positioning~5. Regulation of Nutrition and Liquid Management
Study NCT05422469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept RC neurostimulator
Description: Medtronic SenSight directional DBS leads and implanted pulse generators (IPGs) will be implanted
Study NCT03270163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple electrical stimulations,~* three electrical doublets at the frequency of 100Hz~For each type of electrical stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals.
Study NCT03270163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation
Description: The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple magnetic stimulations,~* three magnetic doublets at the frequency of 100Hz~For each type of magnetic stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals.
Study NCT03270163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound measurement
Description: The ultrasound measurement of the thickness of the quadriceps muscle will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening.
Study NCT06345118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Otago exercise program
Description: The OEP consists of 17 strength and balance exercises and a walking program performed thrice a week by the older adult at home.~Program Prescription The program is designed to be delivered over 6 months and includes a minimum of 5 visits. The first visit is Day 1 of Otago when performance of the functional measures is assessed, and the exercises are prescribed at the Rehabilitation Center of the National Geriatric Hospital. Then, the therapist will see the patient for 4 visits over an 8-week period (typically every other week). This is considered the initial bolus of Otago. Then, the therapist will follow the patient via phone calls every week and make a visit at three months, four months, five months, and six months to reassess the patient's training ability and compliance.~Monitoring:~Calendars can be completed each month to document any falls. A calendar or diary can be used to monitor compliance with the exercise programme
Study NCT06085209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The truFreeze Spray Cryotherapy
Description: A novel FDA cleared technique that allows for liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
Study NCT06085209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ballon dilation
Description: An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3-9 atm) using a syringe and pressure manometer.
Study NCT06085209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ballon dilation
Description: An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3-9 atm) using a syringe and pressure manometer.
Study NCT06085209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial Incision
Description: Carbon dioxide (CO2) laser or Monopolar electrocautery knife
Study NCT06085209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Incision
Description: Carbon dioxide (CO2) laser or Monopolar electrocautery knife
Study NCT06168578 — intervention group
Intervention type: DEVICE
Intervention: ultrasound
Description: Optic nerve diameter will be measured by ultrasound at certain stages of the operation in Group I (ARM-) and Group II (ARM+)
Study NCT06054464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: Part 1 and Part 2: Single, oral dose of PC14586 on day 1 and single, oral dose of PC14586 on day 14.
Study NCT06054464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Part 1: Daily oral dose of rabeprazole on days 11-14.
Study NCT06054464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Part 2: Twice daily oral dose of famotidine on days 11-13. Single, oral dose of famotidine on day 14.
Study NCT04782310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.
Study NCT04782310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine 30mg two hour preoperatively ...will be continued for one week once per day after breakfast .
Study NCT05232149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib( lower dose)
Description: Orelabrutinib is a white, round, uncoated tablet, will be taken lower dose QD by patients with persistent or chronic primary immune thrombocytopenia
Study NCT05232149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib( higher dose)
Description: Orelabrutinib is a white, round, uncoated tablet, will be taken higher dose QD by patients with persistent or chronic primary immune thrombocytopenia
Study NCT05993195 — intervention group
Intervention type: DEVICE
Intervention: Conduit Titanium Interbody Graft
Description: The Concorde Bullet Device is compared with Conduit Titanium Interbody Graft for lumber fusion in terms of reoperation rates at 2 years.
Study NCT05993195 — intervention group
Intervention type: DEVICE
Intervention: Concorde Bullet Device
Description: This traditional device is to compare the clinical results of the new Conduit Titanium Interbody device for lumbar fusion
Study NCT05760937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986447
Description: Specified dose on specified days
Study NCT05760937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT04916197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine prolonged sedation
Description: Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.
Study NCT04916197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.
Study NCT06211348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genomic Sequencing
Description: Individuals who request prenatal diagnostic testing with standard chromosomal microarray will be offered genomic sequencing (GS) as an option to assess for additional disease risk.
Study NCT06141408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MPowerment Stigma-reduction Intervention
Description: In-person events will focus on five specific goals: Fostering a sense of community acceptance and social connection among Black sexual minority men (BSMM), promoting self-acceptance of sexual identity, teaching skills for coping with experiences of racism, reducing PrEP stigma, and providing education on HIV risk. In accordance with the MPowerment model, In collaboration with the PI, the BSMM core group and volunteers would lead the development, implementation, and evaluation of all intervention events. Both peer leaders and the primary investigator (all BSMM) will collaborate to develop specific events (M-Groups), guided by the findings in both the quantitative and qualitative studies. M-Groups will be held once every month. Events will be 2 hour in-person activities focused on the aforementioned goals.
Study NCT05159921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to an automated conversational agent (SurgInfoBot)
Description: See above under arm/group descriptions.